Literature DB >> 6824566

An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole.

P R Twentyman, P Workman.   

Abstract

Experiments have been carried out both in vitro and in vivo to examine the possibility of chemosensitization by misonidazole (MISO) at concentrations which are achievable in the clinic. Using multicellular tumour spheroids in vitro we found that a 16 h pre-incubation with 100 micrograms ml-1 MISO under hypoxic conditions led to a considerable enhancement of sensitivity to melphalan (MEL) but not to CCNU. Pre-incubation for 16 h under hypoxia alone also produced a degree of sensitization to MEL, but there was no effect of oxic pre-incubation with MISO. In vivo experiments using the KHT or RIF-1 tumours in C3H mice were designed so that repeated administration of MISO maintained blood concentrations of around 100 micrograms ml-1 for either 7 h or 16 h. For the 7 h regime, cytotoxic drugs were administered at the 4 h point. In most experiments the tumour response to MEL, cyclosphosphamide (CTX), chlorambucil or CCNU was no greater in mice receiving multiple MISO than in mice receiving multiple injections of a balanced salt solution. In the occasional experiment where there was an apparent increase in response, the effect was only small (dose modifying factor less than 1.5). For the 16 h regime the effect was studied of administering CTX (100 mg kg-1) at various times during the regime. There was a clear trend towards increased CTX response in mice receiving multiple MISO compared with controls. There was, however, no clear tendency for the effect to increase with length of MISO pre-exposure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6824566      PMCID: PMC2011280          DOI: 10.1038/bjc.1983.26

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin.

Authors:  P R Twentyman; R F Kallman; J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-08       Impact factor: 7.038

2.  Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography.

Authors:  P Workman; C J Little; T R Marten; A D Dale; R J Ruane; I R Flockhart; N M Bleehen
Journal:  J Chromatogr       Date:  1978-05-01

3.  Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors.

Authors:  R F Kallman; G Silini; L M Van Putten
Journal:  J Natl Cancer Inst       Date:  1967-09       Impact factor: 13.506

4.  Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.

Authors:  J J Clement; M S Gorman; I Wodinsky; R Catane; R K Johnson
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

5.  A new mouse tumor model system (RIF-1) for comparison of end-point studies.

Authors:  P R Twentyman; J M Brown; J W Gray; A J Franko; M A Scoles; R F Kallman
Journal:  J Natl Cancer Inst       Date:  1980-03       Impact factor: 13.506

6.  The interaction of misonidazole with radiation, chemotherapeutic agents, or heat: a preliminary report.

Authors:  I J Stratford; G E Adams; M R Horsman; S Kandaiya; S Rajaratnam; E Smith; C Williamson
Journal:  Cancer Clin Trials       Date:  1980

7.  Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.

Authors:  P R Twentyman
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

8.  In vivo combination of misonidazole and the chemotherapeutic agent CCNU.

Authors:  D W Siemann
Journal:  Br J Cancer       Date:  1981-03       Impact factor: 7.640

9.  In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.

Authors:  I F Tannock
Journal:  Br J Cancer       Date:  1980-12       Impact factor: 7.640

10.  Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.

Authors:  P Workman
Journal:  Br J Cancer       Date:  1979-09       Impact factor: 7.640

View more
  10 in total

1.  Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.

Authors:  F Y Lee; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Misonidazole reduces blood flow in two experimental murine tumours.

Authors:  J C Murray; V S Randhawa
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

3.  Factors influencing the chemosensitization of melphalan by misonidazole.

Authors:  V S Randhawa; F A Stewart; J Denekamp; M R Stratford
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

4.  The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.

Authors:  M Hinchliffe; N J McNally; M R Stratford
Journal:  Br J Cancer       Date:  1983-09       Impact factor: 7.640

5.  Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.

Authors:  M R Horsman; J W Evans; J M Brown
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

6.  Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

7.  Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

8.  Chemosensitization by lipophilic nitroimidazoles.

Authors:  P R Twentyman; P Workman
Journal:  Br J Cancer       Date:  1983-07       Impact factor: 7.640

9.  Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole.

Authors:  N J McNally; M Hinchliffe; J de Ronde
Journal:  Br J Cancer       Date:  1983-08       Impact factor: 7.640

10.  Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans.

Authors:  B J McDermott; H W Van den Berg; W M Martin; R F Murphy
Journal:  Br J Cancer       Date:  1983-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.